Ozempic Works: But Your Muscles Pay the Price

Ozempic Works: But Your Muscles Pay the Price

There is a moment, somewhere around the third month on a GLP-1 drug, when the numbers on the scale start to move in the direction everyone hoped for. The appetite quiets. The cravings — that low-grade noise that never quite stops — go still. For millions of people in the United States and across Europe, this has felt like the first real silence in years.

The science, increasingly, agrees that something real is happening. GLP-1 medications like semaglutide and tirzepatide have demonstrated measurable cardiovascular benefits — reduced stroke risk, lower rates of heart attack — in populations where both obesity and heart disease have long been intertwined. The drugs are doing what they were designed to do, and then some.

But there is another number that the conversation keeps stepping around.

For adults over 65, new clinical data suggests that GLP-1 medications may be accelerating muscle loss at a rate that carries its own risk profile. Not the dramatic risk of a cardiovascular event, but the quieter, more incremental risk of frailty — the kind that shows up as a fall in a kitchen, a difficulty rising from a chair, a body that has become lighter but not stronger. Researchers note that the drugs suppress appetite so effectively that many older users reduce their protein intake alongside everything else, creating a deficit the body resolves by consuming its own muscle tissue. Dehydration and early markers of malnutrition have also appeared in the data.

This is not a reason to dismiss the medications. It is a reason to understand them more completely than the headlines tend to allow.

The clinical picture that is emerging is actually more interesting than the binary the internet prefers — miracle drug or dangerous shortcut. GLP-1 drugs appear to be genuinely powerful tools for specific populations, with genuinely specific risks for others. Younger adults with obesity and cardiac risk factors may find substantial benefit. Older adults with lower baseline muscle mass may need a different calculus entirely, or at minimum a protein strategy that runs alongside the prescription.

What the research keeps pointing toward — the thread that connects the cardiovascular benefits and the muscle loss data and the emerging work on appetite neurology — is that these drugs change the body's relationship with food at a level that demands deliberate attention to what remains on the plate, not just how much of it.

The drug can quiet the noise. The work of eating well still has to be chosen.

One thing to do: If you or someone you know is over 60 and using a GLP-1 medication, ask the prescribing doctor specifically about protein targets — most guidelines suggest 1.2 to 1.6 grams per kilogram of body weight daily — and consider adding a simple resistance exercise to the routine, even ten minutes three times a week. The scale is not the only number worth watching.